IDCRC Investigator Profile: Judith M. Martin, MD

University of Pittsburgh

Judith (Judy) M. Martin, MD, is a professor of pediatrics at the University of Pittsburgh. Since 1998, Dr. Martin's research has focused on common pediatric infectious diseases and evaluating the effectiveness of vaccines and treatments.

She is nationally recognized for her expertise in managing streptococcal pharyngitis, having conducted longitudinal studies on group A streptococcal infections in school-aged children. Her clinical research also covers acute otitis media, community-acquired pneumonia, urinary tract infections, sinusitis, respiratory viral infections, and vaccine studies.

Dr. Martin currently serves as a site principal investigator for the IDCRC study, "The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products."

How long have you been with the VTEU?

I’ve been involved with the Vaccine and Treatment Evaluation Unit (VTEU) since its establishment in Pittsburgh in late 2019, as a subsite of Vanderbilt. Before that, our clinical trials unit had worked on several pivotal studies with the National Institute of Allergy and Infectious Diseases's
Division of Microbiology and Infectious Diseases (DMID), Vanderbilt, and C. Buddy Creech, MD, MPH.

Can you share more about a current IDCRC study you're working on?

It is such an exciting time to be part of a broader effort to improve protection against respiratory syncytial virus (RSV) in vulnerable pediatric populations. Currently, our team is participating in the PROMISE 24-003 study evaluating maternal vaccination and monoclonal antibody immunization for the prevention of RSV in infants.

Briefly describe your background in infectious disease research, including any past work on IDCRC studies.

We’ve supported multiple IDCRC trials, including several SARS-CoV-2 vaccine studies during the pandemic, enrolling hundreds of adult and pediatric participants. These trials included mRNA, viral vector, and protein subunit vaccines. We helped to provide critical data in studies of immunogenicity, heterologous boosting, and durability of response. We also enrolled adolescents in the Mpox vaccine studies, which led to important information showing that the vaccine is safe and generates a robust antibody response equivalent to that seen in adults.

Of these trials, what has been the most impactful or highlight of the work?

The most impactful work has been our contribution to the early COVID-19 vaccine trials, which helped generate critical data to support emergency use authorizations and public health decision-making. All of the VTEUs' sites worked together tirelessly to make this happen. It was a privilege to be part of a national effort that had such an immediate and far-reaching impact.

What is a strength or example of the importance of the IDCRC?

The IDCRC’s strength lies in its ability to rapidly mobilize a network of experienced investigators and infrastructure to respond to emerging infectious disease threats. Its collaborative model ensures high-quality, timely research that informs clinical practice and public health policy. The collaborative relationships among institutions are a vital asset to the consortium. Now, more than ever, it is important that we work together to keep science moving forward.

What do you like to do outside of the VTEU?

Outside of work, I recharge by laughing with my family, running along country roads with my dog, and reading. I am always looking to learn something new each day. For those who have asked why my Zoom profile picture is Yoda, it is because I consider myself a Jedi in training. Clinical research often requires patience, precision, and a sense of purpose. Yoda reminds me to approach each challenge with curiosity, humility, and calm.